Research & Development
Our R&D strategy is led by a world-class in-house development team and supplemented by creative product development partnerships with external stakeholders. The focus of our R&D strategies is ensuring the ongoing innovation of important and value-generating products across our portfolios.
A proven track record of innovation for patients
The graphic below reflects the timing of when a new product in each dosage form category was initially launched by Amneal or is expected to launch.
2002: Amneal Founded
2005: Oral Solids
2008: Oral Liquids
2015: Inserts/Implants, Inhalation
2017: Nasal Sprays
2019: Transdermal Patches
2022: Biosimilars, LYVISPAH®
2023: International Expansion
2025: K-127, DHE Autoinjector
*Pending completion of a requested QT safety study to resolve CRL and FDA approval. Data as of November 2023